While specific CD4+ subtypes (Foxp3+ Tregs vs Foxp3- helper cells) were uncharacterized, enhanced MT218-MRMI signals likely reflect combined tumor and T cell EDB-FN secretion, providing a dynamic TME marker of therapeutic response. This evidence concerns the gene FOXP3 and neoplasm.